FDA Approves Bristol Myers Squibb Cancer Drug for Stage IV

Bristol Myers Squibb has secured a major regulatory win as the FDA approves its cancer drug for stage IV. The drug, Opdivo (nivolumab) is for patients with advanced classical Hodgkin lymphoma, marking a shift in how the disease is treated from the start.

The approval allows Opdivo to be used in combination with chemotherapy—doxorubicin, vinblastine, and dacarbazine—for adult and pediatric patients aged 12 years and older with previously untreated Stage III or IV Hodgkin lymphoma. This makes it the first immunotherapy-based combination approved as an initial treatment for this cancer.

The decision is backed by a large clinical trial involving nearly 1,000 patients, where the nivolumab-based regimen showed a significant improvement in progression-free survival compared to the traditional standard of care. The study demonstrated about a 58 percent reduction in the risk of disease progression or death, reinforcing the growing role of immunotherapy in oncology.

Also Read: Containment Strategies in Pharma Facilities

Opdivo works by targeting the PD-1 pathway, helping the immune system detect and attack cancer cells more effectively. With the FDA approves Bristol Myers Squibb cancer drug milestone, immunotherapy is now moving earlier in the treatment journey rather than being reserved for later stages.

However, safety remains a concern. Serious side effects were reported in around 39 percent of patients, while immune-related adverse reactions occurred in about 9 percent, highlighting the need for careful monitoring.

The FDA also converted earlier accelerated approvals of nivolumab into full approvals for patients whose disease has relapsed or progressed after prior treatments, including stem cell transplant.

This approval is expected to redefine the standard of care, especially for younger patients commonly affected by Hodgkin lymphoma.